debt
confidence high
sentiment neutral
materiality 0.60
Alaunos Therapeutics amends SVB loan agreement; raises cash collateral requirement eases account covenant
Alaunos Therapeutics, Inc.
- Third Amendment to Loan & Security Agreement, effective March 30, 2023.
- Cash collateral requirement increased to full outstanding principal plus 5.75% Final Payment, from previous half sum.
- Cash collateral will be reduced proportionally with each scheduled monthly principal and interest payment.
- Operating accounts covenant relaxed: only one account required at SVB instead of all accounts.